Actively Recruiting
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Led by Daiichi Sankyo · Updated on 2026-05-08
420
Participants Needed
5
Research Sites
254 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
CONDITIONS
Official Title
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form before any study procedures
- Adults aged 18 years or older at consent
- Histologically confirmed hematologic malignancy as per WHO classification
- Willing to provide tumor samples as required
- ECOG performance status of 0, 1, or 2 within 14 days before treatment
- Adequate organ and bone marrow function per local lab tests within 14 days before treatment
- Left ventricular ejection fraction of 50% or higher by ECHO or MUGA within 28 days before treatment
- Life expectancy of at least 3 months
- Willing and able to follow study visits, drug schedule, lab tests, and procedures
- Women of childbearing potential meeting protocol criteria
- Male participants able to produce sperm agreeing to protocol criteria
You will not qualify if you...
- Previous allogeneic stem cell transplant
- Previous solid organ transplant
- Inadequate washout period before starting study treatment
- Brain or leptomeningeal disease unless treated and stable for 4 weeks before treatment
- Uncontrolled or significant cardiovascular disease per protocol
- Stroke, transient ischemic attack, or arterial thromboembolic event within 6 months before enrollment
- History or current interstitial lung disease or pneumonitis requiring corticosteroids or suspected but not ruled out by imaging
- Severe lung problems from other illnesses
- Diagnosis of another cancer within 3 years prior to enrollment
- Unresolved toxicities from prior cancer therapies above Grade 1 except hair loss
- Active uncontrolled bacterial, fungal, or viral infections
- Active or uncontrolled hepatitis B, hepatitis C, or HIV infections
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Research Site
New York, New York, United States, 10065
Actively Recruiting
2
Research Site
Lille, France, 59037
Actively Recruiting
3
Research Site
Nagoya, Japan, 464-8681
Actively Recruiting
4
Research Site
Tokyo, Japan, 104-0045
Actively Recruiting
5
Research Site
Tokyo, Japan, 135-8550
Actively Recruiting
Research Team
D
Daiichi Sankyo Contact for Clinical Trial Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here